The International Normalized Ratio during concurrent warfarin and argatroban anticoagulation: differential contributions of each agent and effects of the choice of thromboplastin used.
Hursting
M J
MJ
Texas Biotechnology Corporation, 7000 Fannin Street, Suite 1920, Houston, TX 77030, USA.mhursting@sprintmail.com
Zehnder
J L
JL
Joffrion
J L
JL
Becker
J C
JC
Knappenberger
G D
GD
Schwarz
R P
RP
D000925:Anticoagulants / Q000097:blood*; D001120:Arginine / Q000031:analogs & derivatives; D006801:Humans; D019934:International Normalized Ratio; D010875:Pipecolic Acids / Q000097:blood*; D011517:Prothrombin Time; D013449:Sulfonamides; D013925:Thromboplastin; D014859:Warfarin / Q000097:blood*
D000925:Anticoagulants; D010875:Pipecolic Acids; D013449:Sulfonamides; D014859:Warfarin; D013925:Thromboplastin; D001120:Arginine; C031942:argatroban